RXRβ Knockout 293T Cell Line

Description

RXRβ Knockout 293T Cell Line is engineered from human embryonic kidney 293T cells using CRISPR/Cas9 technology to disrupt the Retinoid X Receptor Beta (RXRβ/NR2B2) gene, a key nuclear hormone receptor that forms heterodimers with other nuclear receptors to regulate gene expression involved in development, metabolism, and homeostasis. This knockout model exhibits impaired nuclear receptor signaling while maintaining 293T cells’ characteristic adherent growth with epithelial morphology and high transfection efficiency. The cell line provides a valuable tool for studying retinoid signaling pathways, lipid metabolism, and neurodevelopmental processes, particularly in research involving PPAR, LXR, and thyroid hormone receptor interactions. Maintained at low passage numbers (<P20) with genetic stability, the knockout efficiency is validated through genomic PCR, Sanger sequencing, and functional reporter assays. The cell line has been rigorously tested and confirmed free of contamination from HIV-1, HBV, HCV, Syphilis, mycoplasma, fungi, yeast, and bacteria.